metabolic measurement News
-
Ativa to validate rapid point-of-care sepsis diagnostics with Dr. James Fackler (Critical Care Medicine, Johns Hopkins
Ativa is honored to be working with Associate Professor James Fackler on developing and validating machine learning applications for critical care using digital blood samples from Ativa’s Diagnostic Workstation. Dr Fackler is a valued member of the Clinical Advisory Board and will advise Ativa on applying point of care hematology and metabolic measurement cards to provide a rapid and ...
-
Seahorse Executive Jay Teich Receives SFRBM CEO Innovator Award
Jay Teich, former Seahorse Bioscience CEO, received the first-ever CEO Innovator Award from the Society for Redox Biology and Medicine (SFRBM). This international award recognizes industry leaders who have transformed the face of scientific research in the areas of redox biology and medicine. Teich received the award in Boston on Nov. 20 during SFRBM 2015, the premier event for cutting-edge ...
-
Optimizing and Accelerating COVID-19 Predictive Modeling
The COVID-19 pandemic has wreaked havoc across the globe. As of July 30, 2021, nearly 197.5 million people have been infected with coronavirus, and 4.2 million people have died. The COVID-19 pandemic has resulted in significant pressure on healthcare systems around the globe. The need for effective diagnostic, prognostic and therapeutic procedures has never been as urgent as it is today. Despite ...
By JADBio
-
How Technology, Early Diagnoses Can Help Turn the Tide on Prostate Cancer Prognosis
Dr. Ali Tinazli's post at the Forbes magazine about "How Technology, Early Diagnoses Can Help Turn The Tide On Prostate Cancer Prognosis" There has never been more hope or promise in the global effort to eradicate cancer. Confidence in finding lifesaving cures is at an all-time high among medical researchers who work tirelessly for a solution. Astounding ...
-
Epinex Diagnostics Enters Digital Health Field - Launches `Am I Diabetic` Mobile Phone App
Epinex Diagnostics, Inc., a Tustin, California USA based biomedical company, commemorates National Diabetes Month by launching the “Am I Diabetic” mobile phone app for iPhone and Android devices. The function of this app is to provide educational information and awareness about diabetes. With over half a billion people around the world suffering from diabetes and millions more at ...
-
Lifespin Announces Expansion of Laboratory Testing Capability
Lifespin GmbH, based in Regensburg (Germany), with offices in Boston, Massachusetts, announced today that it has installed additional Nuclear Magnetic Resonance (NMR) equipment which will double Lifespin’s annual laboratory testing capacity. Lifespin will now be able to scan and create the corresponding digitized, quantitative metabolic profiles involving as many as 300,000 human samples ...
-
Lifespin Launches Commercial Access to its Metabolic Profiler Software and Database for Pharma and Biobank Services
Lifespin GmbH, based in Regensburg (Germany), with offices in Boston, Massachusetts, announced today that it has launched a new commercial service for the pharmaceutical and biobanking industry to assist companies in key phases of research, development, and manufacturing. Immediate applications of Lifespin’s commercial services, which leverages access to Lifespin’s proprietary ...
-
Altimmune Announces Initiation Of 48-Week Phase 2 MOMENTUM Trial Of Pemvidutide In Obesity
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first subject in the 48-week Phase 2 MOMENTUM trial evaluating the safety and efficacy of pemvidutide1 in subjects with obesity or overweight. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and ...
-
Fractyl Health Publishes Two-Year Durability Data After a Single Revita DMR Therapeutic Procedure in Patients with Type 2 Diabetes
REVITA-1 was an open-label cohort study evaluating Revita® in patients with type 2 diabetes on oral anti-diabetic agents but not yet on insulin This is the first publication showing two-year durability of improvements in blood glucose, weight, and broader metabolic parameters with no device- or procedure-related adverse events in long-term follow-up after a single Revita procedure ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you